Mumbai-based Indoco Remedies (Indoco) has entered into a Sale and Lease Agreement with OPC Asset Solution.

The agreements, signed on August 29, cover the sale and subsequent leaseback of part of the movable properties at the company’s Waluj Facility in Aurangabad and its AnaCipher Clinical Research Organisation (CRO) in Hyderabad, Telangana.

Indoco received a total consideration of INR 24.65 crore (including GST) for the sale. Under the lease agreement, the company will lease back the assets for a period of 10 years and 33 days (from August 29, 2025, to September 30, 2035), with total lease fees amounting to INR 34.89 crore (including taxes). A security deposit of INR 2.46 crore has also been paid for the movable assets.

The company clarified that the transaction will not impact its manufacturing or business operations, as it will continue to use the assets on a lease basis.

Earlier this month, Indoco received the final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg, a generic equivalent of Xarelto Tablets (2.5 mg, 10 mg, 15 mg, and 20 mg) marketed by Janssen Pharmaceuticals.

Indoco’s Rivaroxaban Tablets USP are bioequivalent and therapeutically equivalent to the reference listed drug and are being manufactured at its facility in Verna, Goa. The drug is widely used for the treatment of venous thromboembolism (VTE).

A fully integrated, research-oriented pharmaceutical company with a strong global presence, Indoco operates 11 manufacturing facilities, seven for FDFs and four for APIs, supported by a state-of-the-art R&D centre and a CRO facility.